Personalized prostate cancer screening for diverse populations
Official title: Tailored prostate cancer screening: addressing USPSTF priority research gaps in a racially-diverse study population
Funded at Stanford University · NIH-10892880 · Data updated 2026-11-12
This study is looking at a new way to screen for prostate cancer by using men's initial PSA levels to better understand their risk, especially focusing on Black men who are more likely to develop aggressive forms of the disease, with the hope of making screening safer and more effective for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $539,382 |
| NIH project number | 5R01CA283896-02 |
| Project ID | NIH-10892880 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include men, particularly those from racially diverse backgrounds, who are at risk for prostate cancer.
✕Less likely to help
Patients who are not at risk for prostate cancer or those who have already been diagnosed with advanced prostate cancer may not benefit from this research.
What this research studies
This research investigates a tailored approach to prostate cancer screening that uses men's baseline PSA levels to assess their risk of developing aggressive forms of the disease. By focusing on a racially diverse population, particularly Black men who are at higher risk, the study aims to optimize screening intervals and strategies to reduce over-diagnosis and over-treatment. Participants will be monitored over time to evaluate the effectiveness of this risk-stratified screening method, which is supported by some health advisory agencies but requires further validation. The goal is to provide a more efficient and effective screening process that benefits all men, especially those at higher risk.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and personalized prostate cancer screening, reducing unnecessary treatments and improving outcomes for patients.
How similar studies have gone: Previous research has shown promise in risk-stratified screening approaches, but this specific method focusing on a diverse population is relatively novel.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Langston, Marvin Epolian — Stanford University
- Study coordinator: Langston, Marvin Epolian
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.